Erasca (ERAS) IPO Opens Fractionally Lower

Today's IPO for Erasca, Inc. (NASDAQ: ERAS) opened for trading at $15.90 after pricing 18,750,000 shares of common stock at an initial public offering price of $16.00 per share.

J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.

At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

You May Also Be Interested In

• Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: ERAS); Insulet Corporation (NASDAQ: PODD); Photronics, Inc. (NASDAQ: PLAB); and (NASDAQ: NUAI) (formerly known as New Era Helium (NASDAQ: NEHC
• Lyntris files for IPO, plans to list on NYSE under "LYNX"
• Market Technology Acquisition Corp prices $200M IPO on Nasdaq